SPOTLIGHT: Analyst lengthens timeline for Cervarix


A Morgan Stanley analyst is raising the prospect that GlaxoSmithKline's Cervarix could be delayed five years beyond the 2009 approval expected by most analysts on Wall Street. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.